PMID- 32042104
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
VI  - 55
IP  - 9
DP  - 2020 Sep
TI  - A high CD34(+) cell dose is associated with better disease-free survival in 
      patients with low-risk diseases undergoing peripheral blood stem cell 
      transplantation from HLA-matched related donors.
PG  - 1726-1735
LID - 10.1038/s41409-020-0817-5 [doi]
AB  - To elucidate the impact of infused CD34(+) cell doses on transplant outcome, we 
      retrospectively analyzed 851 adult patients who received peripheral blood stem 
      cell transplantation (PBSCT) from human leukocyte antigen (HLA)-matched related 
      donors. The patients were divided into high- and low-CD34 groups at the cutoff 
      value of 4.5 x 10(6)/kg. Overall, the high CD34 group showed early neutrophil and 
      platelet recovery. Stratification of disease risks demonstrated that among the 
      patients with low-risk diseases, the high-CD34 group showed better disease-free 
      survival (DFS) (64.9% vs. 55.5%, P = 0.0415) than did the low-CD34 group, without 
      any increase in graft-versus-host disease (GVHD). Meanwhile, a higher CD34(+) 
      cell dose had no impacts on the outcomes of patients with high-risk diseases. 
      Multivariate analyses for the patients with low-risk diseases revealed that a 
      high CD34(+) cell dose (hazard ratio [HR] 0.72, P = 0.048) and development of 
      grade III-to-IV acute GVHD (HR 1.64, P = 0.018) were significantly associated 
      with DFS. An excessive dose of CD34(+) cells (>8.0 x 10(6)/kg) led to an increase 
      in acute GVHD. By stratification of disease risk, a CD34(+) cell dose between 4.5 
      and 8.0 x 10(6)/kg can be suggested for patients with low-risk diseases who 
      undergo PBSCT from HLA-matched related donors.
FAU - Yokoyama, Yasuhisa
AU  - Yokoyama Y
AUID- ORCID: 0000-0003-0366-4147
AD  - Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, 
      Japan.
FAU - Maie, Koichiro
AU  - Maie K
AUID- ORCID: 0000-0003-2389-7554
AD  - Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, 
      Japan.
FAU - Fukuda, Takahiro
AU  - Fukuda T
AD  - Department of Hematopoietic Stem Cell Transplantation, National Cancer Center 
      Hospital, Tokyo, Japan.
FAU - Uchida, Naoyuki
AU  - Uchida N
AD  - Department of Hematology, Federation of National Public Service Personnel Mutual 
      Aid Associations Toranomon Hospital, Tokyo, Japan.
FAU - Mukae, Junichi
AU  - Mukae J
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital, Tokyo, Japan.
FAU - Sawa, Masashi
AU  - Sawa M
AD  - Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
FAU - Kubo, Kohmei
AU  - Kubo K
AD  - Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.
FAU - Kurokawa, Mineo
AU  - Kurokawa M
AD  - Department of Cell Therapy and Transplantation Medicine, The University of Tokyo 
      Hospital, Tokyo, Japan.
FAU - Nakamae, Hirohisa
AU  - Nakamae H
AD  - Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
FAU - Ichinohe, Tatsuo
AU  - Ichinohe T
AD  - Department of Hematology and Oncology, Research Institute for Radiation Biology 
      and Medicine, Hiroshima University, Hiroshima, Japan.
FAU - Atsuta, Yoshiko
AU  - Atsuta Y
AD  - Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
AD  - Department of Healthcare Administration, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Chiba, Shigeru
AU  - Chiba S
AD  - Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, 
      Japan. schiba-t@md.tsukuba.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200210
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antigens, CD34)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Antigens, CD34
MH  - Disease-Free Survival
MH  - *Graft vs Host Disease
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Retrospective Studies
MH  - Transplantation, Homologous
EDAT- 2020/02/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/02/12 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2020/01/27 00:00 [accepted]
PHST- 2020/01/14 00:00 [revised]
PHST- 2020/02/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/02/12 06:00 [entrez]
AID - 10.1038/s41409-020-0817-5 [pii]
AID - 10.1038/s41409-020-0817-5 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2020 Sep;55(9):1726-1735. doi: 10.1038/s41409-020-0817-5. 
      Epub 2020 Feb 10.